How did Perrigo's revenue and expenses trends shift in Q4 2024?

Perrigo's revenue and expense trends in Q4 2024 are characterized by a stable revenue performance with a slight decline in net income.

1. **Revenue Trends**:
- Perrigo's total revenue for Q4 2024 was $1.14 billion.
- The company's revenue growth rate was -0.02%, indicating a slight contraction in revenue compared to the previous period.
2. **Expense Trends**:
- The net income for Q4 2024 was -$44.5 million, reflecting a significant loss for the period.
- The diluted EPS was -$0.32, suggesting that the company's earnings per share were negative and had decreased by 7.01% from the previous period.
3. **Segmental Analysis**:
- Perrigo's revenue was largely driven by its Consumer Healthcare segment, with sub-segments showing varying levels of revenue generation and declines in net income.
- The Consumer Healthcare Americas segment contributed $1.95 billion in revenue, while the Consumer Healthcare International segment generated $1.68 billion in revenue.
- The Consumer Healthcare segment reported a total revenue of $4.37 billion, which, when combined with the other segments, accounted for the total revenue of $1.14 billion.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|PRGO|PRGO.N|Perrigo|20240101-2024|Consumer Healthcare|4.3733E9|169|
|PRGO|PRGO.N|Perrigo|20240101-2024|Unallocated|0|169|
|PRGO|PRGO.N|Perrigo|20240101-2024|Unallocated|0|169|
|PRGO|PRGO.N|Perrigo|20240101-2024|Unallocated|0|169|
|PRGO|PRGO.N|Perrigo|20240101-2024|Consumer Healthcare|1.082E9|169|
|PRGO|PRGO.N|Perrigo|20240101-2024|Unallocated|0|169|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|PRGO|PRGO.N|Perrigo|2024 Q1|166.66666666666669|2000000|169|
|PRGO|PRGO.N|Perrigo|2024 Q2|-1390.4761904761906|-1.084E8|169|
|PRGO|PRGO.N|Perrigo|2024 Q3|-247.88732394366195|-2.1E7|169|
|PRGO|PRGO.N|Perrigo|2024 Q4|-37.77089783281733|-4.45E7|169|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|PRGO|PRGO.N|Perrigo|2024 Q1|-8.428535161208428|1.0821E9|169|
|PRGO|PRGO.N|Perrigo|2024 Q2|-10.694828597770515|1.0655E9|169|
|PRGO|PRGO.N|Perrigo|2024 Q3|-3.230112119594234|1.0875E9|169|
|PRGO|PRGO.N|Perrigo|2024 Q4|-1.607744835335811|1.1383E9|169|

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|PRGO|PRGO.N|Perrigo|2024 Q1|150|0.01|169|
|PRGO|PRGO.N|Perrigo|2024 Q2|-1416.6666666666667|-0.79|169|
|PRGO|PRGO.N|Perrigo|2024 Q3|-250|-0.15|169|
|PRGO|PRGO.N|Perrigo|2024 Q4|-33.33333333333334|-0.32|169|

In conclusion, Perrigo's Q4 2024 financial performance showed a stable revenue output with a slight negative trend, primarily driven by the Consumer Healthcare segments. However, the company experienced a significant net loss, which was a notable shift from any potential gains or breakeven.